Edgar Filing: ARRAY BIOPHARMA INC - Form 4

ARRAY BIOPHARMA INC

Form 4

November 18, 2002

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

FORM 4

Washington, D.C. 20549

OMB APPROVAL

o Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response 0.5

t) (Middle Γ 80301 (Zip)		I.R.S. Identification Number of Reporting Person, if an entity (voluntary)	5.	11/15/0 If Amer of Orig	Day/Year 2 ndment, Date	= e 7.		NG OFFICER, NG OFF	OPMENT		
80301		an entity (voluntary)	5.	If Amer	ndment, Dat	= e 7.	Individual or Joint (Check Applicable X Form filed Form filed	Group Filing Line) by One Reportir by More than	OPMENT		
	Tabl		5.	of Orig	inal	e 7.	(Check Applicable X Form filed Form filed	Line) by One Reportir by More than	ig Person		
	Tabl										
(Zip)	Tabl						One Reporting Person				
Exe if a	emed ecution Dat ny	(Instr. 8)		Securitie or Dispo	s Acquired (. Nature of Indirect Beneficial Ownership (Instr. 4)		
		Code V		Amount	(A) Prio	e					
11/	15/02	S(1)		4,900	D \$8.7	71	1,367,611	D			
							100,000	I	(2)		
	Exe if a Day/Year) (Me	Execution Date if any Day/Year) (Month/Day/Y	Execution Date, Code if any (Instr. 8) Day/Year) (Month/Day/Year) Code V	Execution Date, Code if any (Instr. 8) Day/Year) (Month/Day/Year) Code V	Execution Date, Code or Dispo if any (Instr. 8) (Instr. 3, Day/Year) (Month/Day/Year) Code V Amount	Execution Date, Code or Disposed of (D) if any (Instr. 8) (Instr. 3, 4 and 5) Oay/Year) (Month/Day/Year) Code V Amount (A) Price or (D)	Execution Date, Code or Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5) Day/Year) (Month/Day/Year) Code V Amount (A) Price or (D)	Execution Date, if any (Instr. 8) (Instr. 3, 4 and 5) Oay/Year) (Month/Day/Year) Code V Amount (A) Price or (D) 11/15/02 S(1) 4,900 D \$8.71 1,367,611	Execution Date, if any (Instr. 8) (Instr. 3, 4 and 5) (Instr. 4) (Instr. 4) (Instr. 3 and 4) (Instr		

Edgar Filing: ARRAY BIOPHARMA INC - Form 4

ORM 4 (Continued)	Table II Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)													
Derivative Security I (Instr. 3)	Conversion 3. Tor Exercise (Price of Derivative Security	Гransaction I Month/Day/		Deemed Ex Date, if any (Month/Day	,	. Transa Code (Instr.		D S A D	erivat ecurit cquire ispose nstr. 3	ive	6.	Date Exer Expiration (Month/D	n Date	
					•	Code	V	(1	A)	(D)		Date Exercisab	le	Expiration Date
Tide and America of	Tio de alexin e	0	Price of De	··4	. Numbe	f		10	0	hi E		£ 11	N-4	e of Indirec
Title and Amount of Securities (Instr. 3 and 4)	Underlying	8.	Security (Instr. 5)	ivative 9	Deriva Securit Benefi Follow	tive ies cially Ow ing Reportion(s)		10.	Deriv Secu	ership For vative rities: Dire or Indirect r. 4)	ect		Benefi Owner (Instr.	icial rship
	Amount or Nu	mber												

	Edgar Filing: ARRAY BIOPHARMA INC	- Form 4					
xplanati	on of Responses:						
1)	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted	by the reporting person on September 30, 2002.					
2)	These shares are held in trust for the benefit of the reporting person's children.						
	/s/ David L. Snitman	November 18, 2002					
	**Signature of Reporting Person	Date					
Remin	der: Report on a separate line for each class of securities beneficially owned directly or indirect	ly.					
	* If the form is filed by more than one reporting person, <i>see</i> Instruction 4(b)(v).						
	** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).						
	** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See	18 U.S.C. 1001 and 15 U.S.C. 78ff(a).					